Genomics

EpiVax Oncology Inc. Announces It Has Reduced the Timeline of Its Personalized Neoantigen Therapeutic Cancer Vaccine Process to Under Four Weeks

Thursday, March 26, 2020 - 8:42pm

EpiVax Oncology, Inc ., a precision cancer immunotherapy company, today announced it has reduced the timeline from biopsy to vaccine to under 4 weeks for its personalized neoantigen therapeutic cancer vaccines.

Key Points: 
  • EpiVax Oncology, Inc ., a precision cancer immunotherapy company, today announced it has reduced the timeline from biopsy to vaccine to under 4 weeks for its personalized neoantigen therapeutic cancer vaccines.
  • Previously, the process to create an a personalized vaccine starting from tumor biopsy took at least 12 to 18 weeks.
  • With a personalized cancer vaccine process under 4 weeks, we can safely create a vaccine to treat all stages of aggressive cancer including in the neoadjuvant, adjuvant and metastatic setting.
  • EpiVax Oncology's personalized vaccine design platform, Ancer, incorporates the world-class EpiMatrix system and the innovative JanusMatrix tool, which were exclusively licensed to EpiVax Oncology by EpiVax.

SOPHiA GENETICS and Paragon Genomics Join Forces Against the COVID-19 Coronavirus Pandemic

Thursday, March 26, 2020 - 2:00pm

The new distinctive solution combines Paragon Genomics' CleanPlex SARS-CoV-2 NGS panel reagent kit for whole-genome sequencing of the coronavirus with the advanced analytical power of the SOPHiA Platform for a comprehensive solution to fight the COVID-19 pandemic.

Key Points: 
  • The new distinctive solution combines Paragon Genomics' CleanPlex SARS-CoV-2 NGS panel reagent kit for whole-genome sequencing of the coronavirus with the advanced analytical power of the SOPHiA Platform for a comprehensive solution to fight the COVID-19 pandemic.
  • Through SOPHiA GENETICS global decentralized approach, healthcare institutions worldwide will be able to leverage high quality NGS-based genomic testing in order to scale accurate diagnoses and help address the exponentially growing number of cases.
  • Jurgi Camblong Founder and CEO of SOPHiA GENETICS added, "The current situation is dramatic and diagnostic capabilities haven't scaled as we would have hoped.
  • SOPHiA GENETICS is a health tech company democratizing Data-Driven Medicine to improve health outcomes and economics worldwide.

The single cell sequencing industry analysis projects the market to grow at a significant CAGR of 15.24% during the forecast period, 2019-2029

Thursday, March 26, 2020 - 2:20pm

What are the underlying structures resulting in the emerging trends within the global single cell sequencing market?

Key Points: 
  • What are the underlying structures resulting in the emerging trends within the global single cell sequencing market?
  • What are the key applications in the global single cell sequencing market?
  • The single cell sequencing industry analysis projects the market to grow at a significant CAGR of 15.24% during the forecast period, 2019-2029.
  • The global single cell sequencing market segmentation (on the basis of workflow) is segmented into ingle cell isolation, single cell preparation, and single cell analysis.

SOPHiA GENETICS and Paragon Genomics Join Forces Against the COVID-19 Coronavirus Pandemic

Thursday, March 26, 2020 - 2:00pm

The new distinctive solution combines Paragon Genomics' CleanPlex SARS-CoV-2 NGS panel reagent kit for whole-genome sequencing of the coronavirus with the advanced analytical power of the SOPHiA Platform for a comprehensive solution to fight the COVID-19 pandemic.

Key Points: 
  • The new distinctive solution combines Paragon Genomics' CleanPlex SARS-CoV-2 NGS panel reagent kit for whole-genome sequencing of the coronavirus with the advanced analytical power of the SOPHiA Platform for a comprehensive solution to fight the COVID-19 pandemic.
  • Through SOPHiA GENETICS global decentralized approach, healthcare institutions worldwide will be able to leverage high quality NGS-based genomic testing in order to scale accurate diagnoses and help address the exponentially growing number of cases.
  • Jurgi Camblong Founder and CEO of SOPHiA GENETICS added, "The current situation is dramatic and diagnostic capabilities haven't scaled as we would have hoped.
  • SOPHiA GENETICS is a health tech company democratizing Data-Driven Medicine to improve health outcomes and economics worldwide.

North America Genetic Testing Services Market to 2027 - ResearchAndMarkets.com

Tuesday, March 24, 2020 - 3:34pm

The "North America Genetic Testing Services Market to 2027 - Regional Analysis and Forecasts by Type, Disease, Service Provider and Country" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Genetic Testing Services Market to 2027 - Regional Analysis and Forecasts by Type, Disease, Service Provider and Country" report has been added to ResearchAndMarkets.com's offering.
  • The North America genetic testing services market is expected to reach US$ 7,406.0 Mn in 2027 from US$ 3,044.4 Mn in 2019.
  • Also, growing preference towards Direct-To-Consumer (DTC) genetic testing, support of government to adopt genetic testing services is positively impacting the growth of the market in the review period.
  • North America genetic testing services market is segmented by type, disease, and service provider.

Three Top European Sites Adopt Bionano Saphyr® for Cancer, Genetics, and Cytogenetic Applications

Monday, March 23, 2020 - 12:00pm

The Saphyr system is designed to enable comprehensive analysis of genome structure, including genomic structural variations unresolved by current next-generation sequencing (NGS) technology.

Key Points: 
  • The Saphyr system is designed to enable comprehensive analysis of genome structure, including genomic structural variations unresolved by current next-generation sequencing (NGS) technology.
  • With these installations, the total number of Saphyr systems installed at customer sites to date is 84.
  • The Institut Curie in Paris purchased a Saphyr system in January 2020 thanks to the support of Region Ile de France.
  • Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing.

DNAstack Launches COVID-19 Beacon to Accelerate Sharing Genomic Data in the Fight Against Novel Coronavirus

Friday, March 20, 2020 - 11:06am

"What we know about the virus is changing hourly as researchers and clinicians accumulate and analyze data.

Key Points: 
  • "What we know about the virus is changing hourly as researchers and clinicians accumulate and analyze data.
  • At DNAstack, we are looking to deploy our technologies for biomedical data access, discovery, and analysis to support researchers investigating the virus, starting with Beacon.
  • The COVID-19 Beacon is compliant with the Beacon API, an internationally recognized open-source protocol developed by the Global Alliance for Genomic and Health (GA4GH).
  • DNAstack develops standards and technologies for scientists to more efficiently find, access, and analyze the world's exponentially growing volumes of genomic and biomedical data.

RB Brings Digital R&D Advances to Popular Consumer Products Through Collaboration with Eagle Genomics

Thursday, March 19, 2020 - 3:27pm

PARSIPPANY, N.J., March 19, 2020 /PRNewswire/ -- Global health and hygiene company RB, maker of Lysol, Air Wick, Mucinex, Enfamil and more, today announced a collaboration with life sciences knowledge discovery platform company Eagle Genomics.

Key Points: 
  • PARSIPPANY, N.J., March 19, 2020 /PRNewswire/ -- Global health and hygiene company RB, maker of Lysol, Air Wick, Mucinex, Enfamil and more, today announced a collaboration with life sciences knowledge discovery platform company Eagle Genomics.
  • Following a successful pilot program, the collaboration is expected to accelerate RB's research and development process to simplify the development of new and improved consumer products.
  • "With this partnership, Eagle Genomics and RB will create a collaborative, cloud-based data management and analytics platform on which RB will be able to organize and compound their R&D technical expertise," said Anthony Finbow, CEO at Eagle Genomics.
  • In its initial case study, RB utilized Eagle Genomics' platform algorithms to process over 50 databases and 140,000 publications containing nearly 100,000,000 compounds in record time.

Global Genomics Market (2020 to 2027) - Key Players Include Thermo Fisher Scientific, Life Technologies & Affymetrix Among Others - ResearchAndMarkets.com

Monday, March 16, 2020 - 3:30pm

The global genomics market size is expected to reach USD 31.1 billion by 2027, registering a CAGR of 7.7% over the forecast period according to this report.

Key Points: 
  • The global genomics market size is expected to reach USD 31.1 billion by 2027, registering a CAGR of 7.7% over the forecast period according to this report.
  • Significant changes in disease management processes along with advancements in genomics and personalized medicine are expected to propel the market.
  • Increasing pool of market innovators such as 23andMe, Oxford Nanopore Technologies, and Veritas Genetics that have launched breakthrough genomic technologies in recent years are also contributing toward market development.
  • 23andMe has expertise in developing direct-to-consumer genomic tests targeted toward disease prognosis and has recently received FDA approval for its commercialization.

BC researchers are exploring the use of genomics to improve drug treatments for people with depression

Friday, March 13, 2020 - 5:00pm

This is one of the strongest examples to show how precision health holds real potential to end the trial-and-error approach to therapy.

Key Points: 
  • This is one of the strongest examples to show how precision health holds real potential to end the trial-and-error approach to therapy.
  • However, there are still many questions to be answered before there can be wider adoption of pharmacogenomic testing in a clinical setting.
  • Pharmacogenomics shows significant potential for delivering precision health care, said Dr. Ellie Griffith, Sector Director, Health at Genome BC.
  • Genome British Columbia leads genomics innovation on Canadas West Coast and facilitates the integration of genomics into society.